Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

What are the liver enzyme requirements for starting terbinafine
Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026

How much is biktarvy a month?

See the DrugPatentWatch profile for biktarvy

Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a once‑daily oral medication used in the treatment of HIV‑positive adults. Because it’s a brand‑name product with no available generic (as of 2026), the price can be relatively high compared to other HIV regimens.

Rough Retail Price (U.S.)

Source Approximate Cost per Month*
Manufacturer (Gilead) – list price $2,400 – $2,700
Average Pharmacy Retail $2,300 – $2,600
Insurance‑Covered Cost Varies widely; often $100 – $400 after copay/coinsurance (depending on plan, deductible, and pharmacy network).

*These figures reflect the average out‑of‑pocket price for a 30‑day supply before insurance or discount programs. Prices can fluctuate with changes in manufacturer pricing, pharmacy discounts, or insurance plan design.

How the Cost Can Change

Factor What Happens
Insurance Coverage Most major insurers cover Biktarvy, but copays/coinsurance differ. Some plans offer a “preferred drug list” that reduces cost.
Prescription Fill Method Filling at a large pharmacy chain (e.g., CVS, Walgreens) or an online mail‑order pharmacy can affect copays.
Patient Assistance Programs Gilead offers a Biktarvy Patient Assistance Program (PAP) for qualifying patients who are uninsured or underinsured. Eligibility is based on income, insurance status, and HIV diagnosis.
Manufacturer Discount Cards Gilead’s discount card (when insurance isn’t an option) can lower the out‑of‑pocket cost, but still typically leaves patients with a few hundred dollars/month.
Co‑payment Assistance Some insurers have “co‑pay cards” that reduce the copay to $0 for certain drugs, including Biktarvy.
State or Local Programs A few states offer Medicaid or special assistance programs that further lower costs.

Tips for Managing Cost

  1. Ask Your Provider About the PAP – They can help you apply online or provide a referral letter.
  2. Check Pharmacy Networks – Some pharmacy benefit managers (PBMs) negotiate lower copays with certain chains.
  3. Use a Mail‑Order Pharmacy – Many patients find that mail‑order plans reduce the copay and ensure a steady supply.
  4. Ask About Generic Alternatives – Currently, no generic version of Biktarvy is available, but other once‑daily HIV regimens (e.g., dolutegravir + lamivudine + abacavir) might be cheaper for some patients.
  5. Review Your Insurance Plan Annually – Switching to a plan with a higher deductible but lower drug copays can sometimes save money.

Bottom Line

  • Retail (no insurance): Roughly $2,400–$2,700/month.
  • With insurance: Out‑of‑pocket costs usually fall somewhere between $100–$400/month, depending on the specific plan.
  • Assistance Programs: Available and can bring the cost down to a few dollars a month for qualifying patients.

If you’re looking for the most accurate estimate for your situation, the quickest route is to call your pharmacy or insurance provider. They can pull your specific formulary, copay, and any applicable discount or assistance program.



Other Questions About Biktarvy :

Does biktarvy interact with common multivitamins? What should i do if i miss a dose of biktarvy? Biktarvy patent? Biktarvy costa rica? Biktarvy out of pocket cost? Biktarvy cost without insurance? Generic biktarvy?

AI-Drug Label Prescribing Information Alignment Report

100
100%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The provided content is consistent with the label excerpts for BIKTARVY regarding HBV testing, risk of severe acute hepatitis B exacerbation after discontinuation, and patient counseling not to discontinue without provider input.

Category Scores

Indication
100
Excellent
Indication
100
Excellent
Indication
100
Excellent

Accurate Statements

Patients with HIV-1 should be tested for the presence of chronic HBV before or when initiating antiretroviral therapy.
5.1 and 2.1 (HBV testing prior to or when initiating BIKTARVY)
Severe acute exacerbations of hepatitis B have been reported in patients with HIV-1 and HBV who have discontinued products containing FTC and/or TDF, and may occur with discontinuation of BIKTARVY.
5.1
Patients with HIV-1 and HBV who discontinue BIKTARVY should be closely monitored with clinical and laboratory follow-up for at least several months after stopping treatment.
5.1
If appropriate, anti-hepatitis B therapy may be warranted, especially in patients with advanced liver disease or cirrhosis.
5.1
Severe acute exacerbations of hepatitis B have been reported in patients with HBV and HIV-1 who have discontinued products containing FTC and/or TDF, and may occur with discontinuation of BIKTARVY.
17 (Patient Counseling Information)
Advise the patient not to discontinue BIKTARVY without first informing their healthcare provider.
17

Unsupported Statements

Contradictions

Important Omissions

No full labeling evaluation was possible beyond the provided excerpts because no additional AI response claims were supplied for assessment (e.g., dosage specifics, contraindications, boxed warnings, drug interactions, adverse reactions, storage/handling).
Importance: Low

Safety Assessment

Potential Patient Risk: Low
The evaluated statements align with label warnings/precautions and patient counseling regarding HBV testing and post-discontinuation HBV exacerbation monitoring.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement